Parenti M, Pasquali R, Bianchi V, Barillari C, Vezzadini P
Minerva Med. 1979 Feb 18;70(8):587-93.
A group of patients with athero-arteriosclerotic vascular disease (coronary heart disease and atherosclerosis of the extremities) have been subjected to platelet antiaggregating-antidyslipidaemic treatment with a chlofibrate-dipyridamol association; a control series was treated with chlofibrate alone. Frequency of angina pectoris, pain intensity and trinitrine consumption ware evaluated in patients with coronary heart disease, claudicometry, oscillometry and thermometry in patients with atherosclerosis of the extremities. The following laboratory parameters were also analysed: cholesterolaemia, triglyceridaemia, prothrombin activity, fibrinogenaemia, uricaemia and tolerance of oral glucose loading. Analysis of the results has shown that the association improved the parameters considered in statistically significant fashion; chlofibrate alone led to significant modifications of coronaropathic group parameters (with the exception of pain intensity) whereas it did not lead to significant changes in parameters evaluated for atherosclerosis of the extremities. All laboratory parameters were modified favourably by the association to a statistically greater extent than by chlofibrate alone. Both the association and chlofibrate were well tolerated.
一组患有动脉粥样硬化性血管疾病（冠心病和四肢动脉粥样硬化）的患者接受了氯贝丁酯 - 双嘧达莫联合的血小板抗聚集 - 抗血脂异常治疗；一个对照组仅接受氯贝丁酯治疗。对冠心病患者的心绞痛频率、疼痛强度和硝酸甘油消耗量进行了评估，对四肢动脉粥样硬化患者进行了跛行测量、示波测量和体温测量。还分析了以下实验室参数：胆固醇血症、甘油三酯血症、凝血酶原活性、纤维蛋白原血症、尿酸血症和口服葡萄糖耐量。结果分析表明，联合用药以统计学上显著的方式改善了所考虑的参数；单独使用氯贝丁酯导致冠心病组参数发生显著改变（疼痛强度除外），而对于四肢动脉粥样硬化所评估的参数没有导致显著变化。联合用药使所有实验室参数得到了比单独使用氯贝丁酯更有利的统计学上更大程度的改善。联合用药和氯贝丁酯的耐受性都很好。
